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Background: S100A7 signaling plays a critical role in the pathogenesis and progression of human breast cancers
but the precise role and mechanism of S100A7 for tumor invasion remains unclear. in the present study, we
investigated whether S100A7 overexpression could be mechanistically associated with the up-regulation of NF-κB,
VEGF and MMP-9, resulting in the promotion of breast cancer cell invasion and growth, and vice versa.
Methods: pcDNA3.1-S100A7 cDNA plasmid was constructed and transfected into the MDA-MB-468 cells.
4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was used to detect cell proliferation, Matrigel
was used to detect cell mobility and invasion in vitro.The MMP-9 and VEGF expression and levels was detected by
western blot and ELISA assay. NF-κB DNA binding activity was detected by Electrophoretic mobility shift assay.
Results: Up-regulation of S100A7 by stable S100A7 cDNA transfection increased cell invasion and proliferation,
whereas downregulation of S100A7 by small interfering RNA in S100A7 cDNA-transfected MDA-MB-468 cells
decreased cell invasion and proliferation. Consistent with these results, we found that the up-regulation of S100A7
increased NF-κB DNA-binding activity and MMP-9 and VEGF expression. Down-regulation of S100A7 in S100A7
cDNA -transfected decreased NF-κB DNA-binding activity and MMP-9 and VEGF expression.
Conclusions: Our data demonstrate that the S100A7 gene controls the proliferation and invasive potential of
human MDA-MB-468 cells through regulation of NF-κB activity and its target genes, such as MMP-9 and VEGF
expression. Down-regulation of S100A7 could be an effective approach for the down-regulation and inactivation of
NF-κB and its target genes, such as MMP-9 and VEGF expression, resulting in the inhibition of invasion and growth.
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Human psoriasin (S100A7) is a small calcium binding
protein, which has been shown to be predominantly
expressed in high-grade ductal carcinoma in situ [1-5].
In addition, its expression is significantly associated with
estrogen receptor (ER) α-negative and nodal metastasis
in invasive ductal tumors [1,3-5]. Furthermore, S100A7
expression is associated with increased angiogenesis [6].
S100A7 has been shown to modulate tumor growth by
activating several signaling pathways [7-9]. Recently, it
has reported that S100A7 enhances breast tumor growth* Correspondence: zhangkj1110@126.com
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reproduction in any medium, provided the orand metastasis in MDA-MB-468 ERα (−) cells by activat-
ing proinflammatory and metastatic pathways [10].
Nuclear factor-kappa B (NF-κB) is an essential transcrip-
tion factor that not only modulates cellular responses to
stress but also plays a pivotal role in inflammation, im-
munity, cell cycle growth and survival. NF-κB regulated
genes have been documented to be involved in cellular
proliferation and invasion along with tumor related angio-
genesis and lymph angiogenesis [11-13]. Dysregulation of
NF-κB associated pathways are seen in multiple malignan-
cies. Its constitutive activation in the clinically aggressive
and prognostically poor ER-negative, Her2-neu positive
and inflammatory breast cancer could form the basis for
its evolution as a potential prognostic and therapeutic
target [14].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mediated expression of a dominant negative NF-κB or by
a proteasome inhibitor, MG132, decreased the vascular
endothelial growth factor (VEGF) mRNA and prevented
angiogenesis [15].
In addition, targeting NF-κB signaling may also inhibit
breast cancer cell invasion through decreasing matrix
metalloproteinase 9 (MMP-9) expression [16]. Emberley
et al. [17] has recently reported that overexpression of
S100A7 in MDA-MB-468 cell lines promotes survival
under conditions of anchorage-independent growth.
This effect is paralleled in part by increased activity of
NF-κB, which is known to mediate prosurvival pathways.
The data suggested that there is significant correlation
between S100A7 and NF-κB activity.
S100A7 is among the most highly expressed genes in
preinvasive breast cancer, is a marker of poor survival
when expressed in invasive disease, and promotes breast
tumor progression in experimental models [1-3,5,10].
However, it has not been established whether S100A7
may be a target for breast cancer therapy. In the present
study, we explored the effect and mechanism of S100A7 si-
lencing on growth and invasion in MDA-MB-468 cell lines.Methods
Cell culture and reagents
MDA-MB-468 cells were obtained from American Type
Culture Collection (ATCC, Shanghai Bioleaf Biotech
Co., Ltd. Shanghai, China). The MDA-MB-468 cells were
grown in (D)MEM with 10% fetal bovine serum and 1%
penicillin/streptomycin. The cells were grown in a hu-
midified atmosphere of 5% CO2 at 37°C. Cells were
seeded in 75 cm2 flasks with 15 ml of growth medium,
unless otherwise mentioned. Antibodies were obtained
as follows: anti-S100A7, MMP-9, VEGF, NF-κB p65 and
GAPDH were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). All secondary antibodies were
obtained from Pierce (Rockford, IL, USA). S100A7 small
interfering RNA (siRNA),VEGF siRNA, MMP-9 siRNA
and siRNA control were obtained from Santa Cruz Bio-
technology. LipofectAMINE 2000 was purchased from
Invitrogen (Burlington, ON, Canada).Plasmid construction and transfections
cDNA of S100A7 (OriGene Technologies, Shanghai,
China) was subcloned into pcDNA3.1. MDA-MB-468
cells were transfected with pcDNA3.1-S100A7 cDNA or
pcDNA3.1 using LipofectAMINE 2000 reagent according
to the manufacturer’s instructions and stable clones
were generated using G418 (400 mg/mL)(CAMBREX
(Walkersville, MD). Stably transfected MDA-MB-468
cells (pcDNA3.1-S100A7 cDNA/MDA-MB-468 and
pcDNA3.1/MDA-MB-468) were transfected with MMP-9siRNA (2 μM) or VEGF siRNA (2 μM) and control siRNA
for 48 hours using LipofectAMINE 2000.
Electrophoretic mobility shift assay
Nuclear extracts were prepared from cells using the
NE-PER nuclear and cytoplasmic extraction reagents kits
according to the manufacturer’s directions (Pierce
Biotech). For NF-κB DNA binding, the 10,000 cpm of the
22-bp oligonucleotide 5′-AGTTGAGGGGACTTTCCCA
GGC-3′ containing the NF-κB consensus sequence that
had been labeled with [−32P]ATP (10 mCi/mmol) by T4
polynucleotide kinase was added to 15 μg nuclear extract.
The reaction was allowed to proceed for 30 minutes
at room temperature. For cold competition experiments,
unlabeled NF-κB oligonucleotide as nonspecific competi-
tor gels were dried and directly exposed to a B-1
phosphorimaging screen and visualized with a GS-250
Molecular Imaging System [Bio-Rad (Hercules, CA,
USA)]. TATA binding protein (TBP) was used as a nuclear
loading control (Abcam Inc. Beijing, China).
MMP-9 activity assay
MMP-9 activities in whole cell lysates were assessed using
the colorimetric Biotrak MMP-9 activity assay (Amersham
Biosciences, Shanghai, China) in accordance with the man-
ufacturer’s instructions. Optical densities were quantified
using a Vmax microplate spectrophotometer at a wave-
length of 405 nm, referenced to 650 nm. Three samples
were used for each experimental condition and experiments
were performed in triplicate and mean values calculated.
VEGF assay
The culture medium of the cells in different groups
grown in six-well plates was collected. After collection,
the medium was spun at 800 × g for 3 minutes at 4°C to
remove cell debris. The supernatant was either frozen
at −20°C for VEGF assay later or assayed immediately
using commercially available ELISA kits (R&D Systems,
Inc., Minneapolis, MN, USA).
Western blot analysis
Cell lysates were prepared from the MDA-MB-468 cells
in different conditions and subjected to Western blot ana-
lysis using an anti-MMP-9, VEGF, S100A7, NF-κB p65 and
an anti-β-actin monoclonal antibody for normalization of
protein loading. Immunoreactivity was detected using the
ECL chemiluminescence system (Amersham, Piscataway,
NJ, USA) and quantified using an imaging densitometer
(Model GS-670; Bio-Rad, Hercules, CA, USA).
Cell proliferation assay
MDA-MB-468 cells were stably transfected with pc.
DNA3.1-S100A7 or pc. DNA3.1. Then the cells were
seeded at a density of 5 × 103 cells per well on 96-well
Figure 1 Effect of S100A7 overexpression by transfection of
S100A7-pcDNA3.1 plasmid on S100A7. Representative images
showing expression of S100A7 in vector (pcDNA3.1), pcDNA3.1-
S100A7 and transfected with S100A7 siRNA in MDA-MB-468 cells as
analyzed by Western blot.
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and cultured in a humidified chamber at 37°C for up
to 3 days. Viable cells were identified using the 3-
(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) assay. Briefly, 200 ul sterile MTT dye (5 mg/ml,
Sigma, USA) was added. After 4 hours incubation at 37°C
in 5% CO2, the MTT medium mixture was removed and
200 ul of dimethyl sulfoxide (DMSO) was added to each
well, as was reported. Absorbance was measured at 540
nm using a multi-well spectrophotometer (Thermo
Electron, Andover, USA). All experiments were carried
out in triplicate.
Determination of cell mobility
The invasiveness of MDA-MB-468 cells was tested after
transfection as previously described. The cells (1 × 106/
mL) were added to the upper wells coated with Matrigel
(1 mg/mL; Collaborative Research, Inc., Boston, MA,
USA) with serum-free medium containing 25 ug/mL
fibronectin as a chemoattractive agent in the lower wells.
After a 24-hour incubation period, cells that migrated
through the filters into the lower chamber were counted
by the number of cells on the lower side of the membrane
in five random fields after staining with Hema-3 kit(Fisher
Scientific (Nepean, Canada).
In vitro cell invasion assay using Matrigel
Cell invasion assays were performed using Transwell
membrane filter inserts with 8-mm pore size (Corning
Costar, Cambridge, MA, USA). The upper surface of the
Transwell membrane was coated with 250 mg/ml of
growth factor-reduced Matrigel matrix(Becton Dickinson,
Bedford, MA, USA) overnight at 4°C, rehydrated once
with 0.1% BSA in (D)MEM for 1 hour at room
temperature, and then placed in the upper compartment
of six-well tissue culture plates.
MDA-MB-468 cells in different conditions were re-
moved from tissue culture flasks by a short exposure to 5
mM ethylenediaminetetraacetic acid (EDTA) and washed
once in PBS. Then 2 × 105 cells in serum-free medium
containing 0.1% BSA were added to each Transwell cham-
ber and allowed to migrate toward the underside of the
membrane for 24 hours in the lower chamber as a chemo-
attractant. After the cells were fixed in 3.5% paraformalde-
hyde, cells on the upper surface of the membrane were
removed by wiping with a cotton swab, and membranes
were mounted onto glass slides. The relative number of
invasion was determined by counting the number of in-
vading EGFP(enhanced green fluorescent protein)-positive
cells. The number of invading cells transfected with empty
vector was assigned a value of 1.0 in each experiment.
Twenty random fields/membrane were counted for each
assay. Each determination represents the average of three
separate experiments.Statistical analysis
One-way analysis of variance was used to compare means.
The level of statistical significance was set at P <0.05, and
all statistical calculations were carried out using SPSS.11
software (SPSS Inc., Chicago, IL, USA).
Results
Effect of S100A7 overexpression on MDA-MB-468 cells
MDA-MB-468 cells stably transfected with pc. DNA3.1-
S100A7 plasmid displayed a significant increase in the
expression levels of S100A7 as compared with vector
control confirmed by performing western blot analysis
(Figure 1). When the pc.DNA3.1-S100A7/MDA-MB-468
cells were transfected with S100A7 siRNA for 48 hours,
S100A7 expression levels were significantly decreased
(Figure 1).
Effect of S100A7 overexpression on invasive capability
We performed an in vitro cell invasion assay using Matrigel
matrix to examine whether S100A7 overexpression
promotes invasive capability in MDA-MB-468 cells.
MDA-MB-468 cells were stably transfected with pc.
DNA3.1-S100A7. Repeated experiments revealed that
MDA-MB-468/ pc.DNA3.1-S100A7 cells showed signifi-
cantly higher invasiveness potential than cells transfected
with vector alone (Figure 2). However, when S100A7 was
silenced by S100A7 siRNA transfection in MDA-MB-468/
pc.DNA3.1-S100A7 cells, invasiveness potential was de-
creased significantly (Figure 2). These results suggest that
S100A7enhances the invasiveness of tumorigenic cells.
Effect of S100A7 overexpression on proliferation
MDA-MB-468 cells were stably transfected with pc.
DNA3.1-S100A7 and cell proliferation was detected by
MTT analysis. As shown in Figure 3, the growth rate of
MDA-MB-468 cells was significantly increased in the pc.
DNA3.1-S100A7 transfected cells. However, the growth
rate of MDA-MB-468 cells silenced by S100A7 siRNA
Figure 2 Effect of S100A7 overexpression on invasiveness of MDA-MB-468 cells transfected with recombinants in Matrigel invasion
assay. Cells were stably transfected with empty vector pc.DNA3.1 or pc.DNA3.1-S100A7, or transfected with S100A7 siRNA. After 2 days, 1 × 105
cells were allowed to invade through transwell inserts (8 μm) coated with Matrigel. The cells on the lower surface of the chambers were stained,
counted, and photographed under a light microscope. Histogram shows invasive capability of transfected cells. Each bar represents mean ± SE
(n = 3); *, P <0.05.
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MDA-MB-468 cells was significant decreased (P <0.05),
suggesting that S100A7 does alter the cell proliferation
rate in MDA-MB-468 cells.
S100A7 overexpression promotes activation of NF-κB
To investigate whether S100A7 overexpression activated
NF-κB in MDA-MB-468 cell lines, western blot was first
done to detect NF-κB p65(RelA) levels. Representative
pictures are shown in Figure 4A. RelA was overexpressed
in MDA-MB-468/pc.DNA3.1-S100A7 cells compared to
the control and MDA-MB-468/pc.DNA3.1 cells. The
NF-κB signaling pathway is involved in cancer cell inva-
sion processes. Therefore, we measured the NF-κB
DNA binding activity in pc.DNA3.1-S100A7 transfected
MDA-MB-468 cells. Nuclear extracts from control and pc.
DNA3.1 or pc.DNA3.1-S100A7–transfected MDA-MB-468
cells were subjected to analysis for NF-κB DNA-binding
activity as measured by electrophoretic mobility shift
assay (EMSA). It was found that up-regulation of
S100A7 by pc.DNA3.1-S100A7 transfection increased
NF-κB DNA-binding activity (Figure 4B). However,
S100A7 silencing by S100A7 siRNA transfection signifi-
cantly induced NF-κB DNA-binding activity in pc.Figure 3 Effect of S100A7 overexpression on cytotoxicity of breast tum
with pc.DNA3.1-S100A7 cells. Cell viability was determined by the MTT assay.
was significantly increased in the MTT assay. Each bar represents mean ± SE (
tetrazolium bromide.DNA3.1-S100A7 stably transfected MDA-MB-468 cells
compared with the control (Figure 4B). These results indi-
cated that S100A7 overexpression increased NF-κB
DNA-binding activity in MDA-MB-468 cancer cells.
The expression of MMP-9 and VEGF is regulated by
NF-κB and has been reported to play an important role
in tumor invasion. We, therefore, investigated whether
MMP-9 and VEGF were involved in invasion induced
by S100A7.
Effect of S100A7 overexpression on MMP-9 expression
and its activity
To explore whether the invasiveness of transfected cells
was associated with MMP-9 induction, Western blotting
was conducted to detect the alteration in the expression
of MMP-9. We found that MDA-MB-468 cells transfected
with pc.DNA3.1-S100A7 exhibited a significant increase
in the expression level of MMP-9 (Figure 5A). However,
S100A7 silencing by S100A7 siRNA transfection signifi-
cantly decreased MMP-9 in pc.DNA3.1-S100A7 stably
transfected MDA-MB-468 cells compared with the
control (Figure 5A). Next, we examined whether
S100A7 overexpression could lead to an increase in
MMP-9 activity. There was a four-fold increase in theor MDA-MB-468 cell lines. MDA-MB-468 cells were stably transfected
The growth rate of the pc.DNA3.1-S100A7 transfected MDA-MB-468 cells
n = 3); **, P <0.01. MTT, 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl
Figure 4 S100A7 overexpression induced NF-κB in the
MDA-MB-468 cells. A, NF-κB p65 expression in investigated
MDA-MB-468 cells was analyzed by western blot. B, EMSA analysis
was done for MDA-MB-468 cells. Nuclear extracts were prepared
from control and transfected cells and subjected to analysis for
NF-κB DNA-binding activity as measured by EMSA. Retinoblastoma
protein level served as the nuclear protein loading control. EMSA,
electrophoretic mobility shift assay; NF-κB, nuclear factor-kappa B.
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that S100A7 silencing decreased the activity of MMP-9
(Figure 5B).
Effect of S100A7 overexpression on VEGF expression and
its activity
We further investigated whether S100A7 expression has
any effect on VEGF induction, whose expression is tran-
scriptionally regulated by NF-κB. Western blotting was
done to detect the expression of VEGF. We found that
VEGF protein levels were dramatically increased in the pc.Figure 5 MMP-9 expression was up-regulated by S100A7 cDNA trans
A, Western blot analysis of MMP-9 protein expression in transfected MDA-M
up-regulated by S100A7 cDNA transfection and down-regulated by S100A7
MMP-9, matrix metalloproteinase 9.DNA3.1-S100A7-transfectedMDA-MB-468 cells (Figure 6A).
Most importantly, we also found that the downregulation
of S100A7 could lead to a decrease in VEGF level in pc.
DNA3.1-S100A7 stably transfected MDA-MB-468 cells
(Figure 6B). Our results also showed that overexpression
of S100A7 increased the level of VEGF, which is consistent
with the regulation of the DNA-binding activity of NF-κB
by S100A7.
Down-regulation of MMP-9 and VEGF decreased cancer
cell invasion
To further confirm the role of MMP-9 and VEGF in
MDA-MB-468 cell invasion, the pc.DNA3.1-S100A7-
transfected MDA-MB-468 cells (stable transfectant)
were transfected with human MMP-9 siRNA or VEGF
siRNA. Down-regulation of MMP-9 or VEGF by siRNA
transfection resulted in low expression of MMP-9 or
VEGF protein, respectively, as confirmed by Western
blot analysis (Figure 7A). To further test whether the
S100A7-induced invasion of MDA-MB-468 cells is
mediated through MMP-9 and VEGF, we used the
Matrigel invasion chamber assay to examine the invasive
potential of MMP-9 siRNA- or VEGF siRNA-transfected
MDA-MB-468 cells that were stably transfected with
S100A7. As illustrated in Figure 7B, both MMP-9
siRNA- and VEGF siRNA–transfected cells showed a
low level of penetration through the Matrigel-coated
membrane compared with the control siRNA–transfected
cells. The value of fluorescence was decreased 4.2-fold
and 1.8.-fold in the invaded MDA-MB-468 cells transfected
with MMP-9 siRNA and VEGF siRNA, respectively,
compared with that of control siRNA (Figure 7B).
However, whether MMP-9 or VEGF downregulation
modulates S100A7 expression in these cells needs
further investigation.fection and down-regulated by S100A7 siRNA transfection.
B-468 cells. B, MMP-9 activity assay showing that MMP-9 was
siRNA transfection. Each bar represents mean ± SE (n = 3); *, P <0.01.
Figure 6 VEGF expression was up-regulated by S100A7 cDNA transfection and down-regulated by S100A7 siRNA transfection.
A, Western blot analysis of VEGF protein expression in transfected MDA-MB-468 cells. B, VEGF activity assay showing that VEGF was up-regulated
by S100A7 cDNA transfection and down-regulated by S100A7 siRNA transfection. Each bar represents mean ± SE (n = 3); *, P <0.05. VEGF, vascular
endothelial growth factor.
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S100A7 is a member of the S100 family of proteins, which
have been associated with preinvasive ductal carcinoma in
situ (DCIS). Persistent expression of S100A7 occurs in
some invasive cancers and is associated with poor prog-
nostic factors [1]. Persistent S100A7 expression also oc-
curs in a subset of invasive breast carcinomas and is linked
to worse clinical outcome [5]. S100A7 has been shown to
be overexpressed in breast cancers at sites of necrosis in
tumor tissues [1,7], as well as in the nasal fluid duringFigure 7 Down-regulation of MMP-9 or VEGF by siRNA transfection d
by siRNA transfection showed low-expression of MMP-9 or VEGF protein in
analysis. B, invasion assay showing that MMP-9 or VEGF siRNA–transfected
membrane, compared with control siRNA-transfected cells. MMP-9, matrix mallergic inflammatory reactions [17]. Although a number
of putative functions have been proposed for S100A7, its
biological role, particularly in breast cancer, remains to be
defined. S100A7 has been reported to increase NF-κB
activity levels in MDA-MB-468 cells [7], and NF-κB-regu-
lated genes have been documented to be involved in
cellular proliferation and invasion along with tumor
related angiogenesis and lymphangiogenesis [18] but not
much is known about the relation between S100A7 and
NF-κB as well as its role in NF-κB-induced signaling.ecreased tumor cell invasion. A, down-regulation of MMP-9 or VEGF
S100A7-transfected MDA-MB-468 cells as confirmed by Western blot
cells exhibited low penetration of cells through the Matrigel-coated
etalloproteinase 9. VEGF, vascular endothelial growth factor.
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effects of S100A7 in MDA-MB-468 breast cancer cells.
We have observed that S100A7 overexpression by cDNA
transfection increased tumor cell invasion and promoted
proliferation but down-regulation of S100A7 by siRNA de-
creased cell invasion and inhibited proliferation. S100A7
overexpression increased NF-κB DNA binding activity and
NF-κB, MMP-9 and VEGF expression levels and activity,
but down-regulation of S100A7 by siRNA decreased
NF-κB DNA binding activity and NF-κB, MMP-9 and
VEGF expression levels and activity. Taken together,
these results further support the view that the
downregulation of S100A7 could be an effective approach
for the inactivation of NF-κB and down-regulation of its
target genes, such as MMP-9 and VEGF expression,
resulting in the inhibition of invasion and proliferation.
NF-κB activation has also been reported to be associated
with metastatic phenotype and to regulate the expression
of a variety of important genes in some cellular responses,
including metastasis related genes such as VEGF and
MMP-9 [19-27]. Because NF-κB plays important roles in
many cellular processes, studies on the interaction of
NF-κB activation with other cell signal transduction
pathways, including the S100A7 pathway, have received
increased attention in recent years. S100A7 has also been
reported to crosstalk with the NF-κB pathway [7]. S100A7
strongly induces NF-κB promoter activity and induces
NF-κB DNA-binding activity [7]. Activation of NF-κB
leads to up-regulation of several downstream target genes,
including MMP-9 and VEGF. Thus, the downregulation
of S100A7 results in lower NF-κB activity and its
downstream targets. Therefore, it is possible that
S100A7-induced cell invasion is partly due to activation
of the NF-κB pathway.
In the present study, we showed that S100A7 over-
expression increased NF-κB expression and NF-κB
DNA-binding activity and concomitantly increased the
expression and activation of MMP-9 and VEGF. However,
downregulation of S100A7 decreased NF-κB expression
and NF-κB DNA-binding activity and concomitantly
inhibited the expression and activation of MMP-9 and
VEGF.
Because we observed that S100A7 overexpression pro-
moted MMP-9 expression, we tested the effects of S100A7
on the invasion of MDA-MB-468 cells. We found that
S100A7 overexpression promoted cell invasion of MDA-
MB-468 cells, and down-regulation of S100A7 inhibited
the cell invasion of MDA-MB-468 cells. These results
are consistent with MMP-9 data, showing that down-
regulation of S100A7 could inhibit cancer cell invasion
partly through downregulation of MMP-9 and vice versa.
There was a trend toward an association between
expression of VEGF and distant metastasis [28]. In this
study, consistent with our invasion data, we found asignificant reduction in the expression of VEGF by
down-regulation of S100A7 and a significant increase in
the expression of VEGF by up-regulation of S100A7. It
is well accepted that the expression of MMP-9 and
VEGF is regulated by NF-κB [20-28]. Down-regulation
of S100A7 inhibited the NF-κB reporter gene and gene
products, such as those involved in cell invasion and vice
versa. Based on our results, we speculate that one
possible mechanism by which S100A7 induces invasion
is due to activation of NF-κB DNA binding activity,
which leads to up-regulation of NF-κB target genes, such
as MMP-9 and VEGF.
On the basis of previous results that S100A7 has been
shown to enhance tumorigenicity in ERα(−) cells, our
study also shows that S100A7 overexpression promoted
proliferation; however, S100A7 silencing inhibited prolif-
eration in the MDA-MB-468 cells. On the basis of our
results, we propose a hypothetical pathway by which
S100A7 may promote cell proliferation of MDA-MB-468
cells partly through the NF-κB signaling pathway. How-
ever, further in-depth studies are needed to investigate
the precise molecular mechanism regarding the cause
and effect relationship between S100A7 and NF-κB.
Conclusions
We demonstrated that the S100A7 gene controls prolif-
eration and invasion of MDA-MB-468 cells at least in
part through the activation of NF-κB and its target
genes, such as MMP-9 and VEGF expression, resulting
in the inhibition of invasion and proliferation, which
could be useful for devising novel preventive and thera-
peutic strategies for breast cancer. This approach could
be realized through development of specific S100A7 in-
hibitors or use of a gene therapy approach.
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